Therapeutic Effects of Probiotic Minas Frescal Cheese on the Attenuation of Ulcerative Colitis in a Murine Model

Abstract

Inflammatory bowel diseases (IBDs) constitute disturbances of gastrointestinal tract that cause irreversible changes in the structure and function of tissues. Ulcerative colitis (UC), the most frequent IBD in the population, is characterized by prominent inflammation of the human colon. Functional foods containing probiotic bacteria have been studied as adjuvants to the treatment or prevention of IBDs. The selected probiotic strain Lactococcus lactis NCDO 2118 (L. lactis NCDO 2118) exhibits immunomodulatory effects, with promising results in UC mouse model induced by dextran sodium sulfate (DSS). Additionally, cheese is a dairy food that presents high nutritional value, besides being a good delivery system that can be used to improve survival and enhance the therapeutic effects of probiotic bacteria in the host. Therefore, this work investigated the probiotic therapeutic effects of an experimental Minas Frescal cheese containing L. lactis NCDO 2118 in DSS-induced colitis in mice. During colitis induction, mice that consumed the probiotic cheese exhibited reduced in the severity of colitis, with attenuated weight loss, lower disease activity index, limited shortening of the colon length, and reduced histopathological score. Moreover, probiotic cheese administration increased gene expression of tight junctions’ proteins zo-1, zo-2, ocln, and cln-1 in the colon and increase IL-10 release in the spleen and lymph nodes. In this way, this work demonstrates that consumption of probiotic Minas Frescal cheese, containing L. lactis NCDO 2118, prevents the inflammatory process during DSS-induced colitis in mice, opening perspectives for the development of new probiotic functional foods for personalized nutrition in the context of IBD.

Lactococcus lactis NCDO2118 exerts visceral antinociceptive properties in rat via GABA production in the gastro-intestinal tract

“…It was also demonstrated that L. lactis may exert in vivo a potent anti-inflammatory activity attenuating colitis ( Nishitani et al, 2009 ; Luerce et al, 2014 ; Ballal et al, 2015 ; Berlec et al, 2017 ; Nomura et al, 1999 ). L. lactis is also able to produce GABA in vitro ( Nomura et al, 1999 ) and the well-characterized NCDO2118 strain besides its probiotic properties ( Cordeiro et al, 2021 ), is considered as an efficient GABA producer among the species ( Oliveira et al, 2017 ; Mazzoli et al, 2010 ; Oliveira et al, 2014 ; Laroute et al, 2016 ; Laroute et al, 2021 ).…”

SlpB Protein Enhances the Probiotic Potential of L. lactis NCDO 2118 in Colitis Mice Model

“…The secretory immunoglobulin A (sIgA) of the intestinal lavage was determined by ELISA, according to Cordeiro et al, 2021 . For the quantification of the samples was used a 96 well-plates (Nunc-Immuno Plates, MaxiSorp) coated with anti-IgA antibodies (Southern Biotechnology, Birmingham, AL, United States) and incubated overnight.…”

“…Probiotics, such as P. freudenreichii CIRM-BIA 129 and L. lactis NCDO 2118, have been tested as adjuvants in the treatment of colitis in animal models ( Gomes-Santos et al, 2017 ; Ma et al, 2020 ; Rabah et al, 2020 ; Cordeiro et al, 2021 ). IBDs induce pathological signs and symptoms such as weight loss, rectal bleeding, diarrhea, shortening of the colon, and destruction of the epithelial layer.…”

Lyophilized Symbiotic Mitigates Mucositis Induced by 5-Fluorouracil

“…The determination of moisture, protein, and fat content were evaluated according to what was previously described (BRASIL, 2006). To determine the moisture content, we oven-dry 5 g of a sample at 100-105 °C, for 24 h. For protein content quantification and fat levels, we realized the Kjeldahl and Gerber method, respectively (Cordeiro et al, 2021). All results were expressed as g/100 g. The bioactive peptides levels were determinated evaluate the angiotensin I-converting enzyme inhibition (ACEI), antioxidant activity (DPPH), and α-amylase and α-glucosidase inhibition.…”